
Frenia4 mg
Incepta Pharmaceuticals Ltd.
Schizophrenia (Established) Risperidone is FDA-approved for the treatment of schizophrenia in adults and in adolescents aged 13 to 17 years.
Risperidone is FDA-approved for the treatment of schizophrenia in adults and in adolescents aged 13 to 17 years.
Risperidone is approved as monotherapy for acute manic or mixed episodes of Bipolar I Disorder in adults and in children and adolescents aged 10 to 17 years. Risperidone is also approved as adjunctive therapy with lithium or valproate for acute manic or mixed episodes of Bipolar I Disorder in adults (Adjunct use).
Risperidone is approved for the treatment of irritability associated with autistic disorder (including symptoms such as aggression, self-injury, and severe tantrums) in children and adolescents aged 5 to 16 years.
Risperidone is sometimes used off-label, under specialist supervision, for other psychotic disorders and severe behavioral disturbances based on clinical judgement; such use of Risperidone is not an FDA-approved indication.
The dose of Risperidone is individualized by indication, age group, and patient response, and must be determined and adjusted only by a qualified healthcare professional. The table below outlines typical starting doses, titration, and target/effective ranges for Risperidone; it is provided for general information and is not a substitute for a prescriber's instructions.
Risperidone is contraindicated in patients with known hypersensitivity to Risperidone or to any component of the Risperidone formulation. No other absolute contraindication to Risperidone is established.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.